SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
CLTR COULTER PHARMACEUTICAL
An SI Board Since January 1997
Posts SubjectMarks Bans Symbol
666 17 0 CLTR
Emcee:  HARRY GIBSON Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
391 Bob, Well I think all of us 'beat this horse to death', so I offer no WTDEC-11/21/1999
390 As most here know, I lean to CHOP-Rit in a marketing sense, if not for data bacscaram(o)uche-11/21/1999
389 Right, pretreatment is as much or more of a factor than the natural variation iBob L-11/21/1999
388 relative tox- You have to be really careful in comparing the relative tox acroRWReeves-11/21/1999
387 I didn't mean to imply anything underhanded in the discussion of safety of Bob L-11/21/1999
386 Yep, I read the quote of Ende. I think he is correct when he suggests "inBob L-11/21/1999
385 Great discussion. This is SI at its best. My view of the data is that Bex has aVector1-11/21/1999
384 Bob, Below is a quote from Eric Ende MD, the IDEC bull who V1 also quoted at MWTDEC-11/20/1999
383 Maybe we are giving different weight to different abstracts. You said, "TBob L-11/20/1999
382 Dosimetry is an important consideration, but I'm not sure I see a weight ofBob L-11/20/1999
381 Thanks for the scientific input, PB. I couldn't help notice that you didWTDEC-11/20/1999
380 Medical theory. There are two. One (IDEC bulls): Coulter simply understates Pseudo Biologist-11/20/1999
379 Bob, It seems to me that in order to make a true direct comparison you need toWTDEC-11/20/1999
378 Bob, IDPh can not use dosemitry in administering Y2B8 and as a result the theraVector1-11/20/1999
377 Walter, Pure frustration. No new info on the filing timing. V1Vector1-11/20/1999
376 "The weight of evidence seems to tilt solidly, if not overwhelmingly, to BBob L-11/20/1999
375 V1, I had a chance to review the most recent research on CLTR from Rachel at WWTDEC-11/20/1999
374 The following is an excerpt from Eric Ende of lehman's recent report on IDPVector1-11/20/1999
373 No, that doesn't count since I didn't have any money to buy it. CLTR,RWReeves-11/19/1999
372 <<CELG? As in 5-6-bagger in a year CELG? -g- where do we send flowers to Miljenko Zuanic-11/19/1999
371 10-12? Well, came pretty darn close, didn't it? Malarky story is right. (nPseudo Biologist-11/19/1999
370 Where are the damn shorts when you need them. I wanted to buy some of this atRWReeves-11/19/1999
369 Bob, thanks I found 11 with bexxar or tosi (for short -g-). A list is given hePseudo Biologist-11/18/1999
368 John: >>Part of the problem was to get the computer data base modified Micawber-11/18/1999
367 I just don't buy the company line on this one. "the FDA wanted to dDr. John M. de Castro-11/18/1999
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News